CAPA In-vitro Oocyte Maturation

In vitro oocyte maturation (IVM) is a mild-approach assisted reproductive technology (ART). Because of its simplicity, the more favorable financial implications (reduced cost) for patients, and the lower health risk profile of IVM compared to controlled ovarian stimulation (COS) in polycystic ovary syndrome (PCOS) patients, the use of IVM in selected patients may gain increasing interest. Besides its application in patients with polycystic ovaries, IVM technology may have a role in fertility preservation, where young girls and adult women are facing infertility due to gonadotoxic chemotherapeutic treatment.

NCT Number	NCT06984081
Lead Sponsor	Chinese University of Hong Kong
Conditions	Infertility, Female
Enrollment	100 participants
Start Date	2025-11-10
Primary Completion	2030-05-31 (estimated)
Study Completion	2032-05-31 (estimated)
Updated on ClinicalTrials.gov	2025-12-08